REGENXBIO Inc. (RGNX) Fair Value 2026

RGNX · Biological Products, (No Diagnostic Substances) ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.3 /10

32 fundamental signals · 9 models active

Value Trap Risk

SAFE (14/100)

Quick Summary — As of 2026-07-15, REGENXBIO Inc. (RGNX) trades at $12.27, approximately 694% above CirclFi’s Bayesian DCF fair value of $1.55. QOC: 6.3/10. Value Trap Risk: 14/100 (SAFE). 9/13 models active.

Key Facts

Ticker
RGNX
Price
$12.27
Quality Score
6.3/10
Value Trap Risk
14/100
Models Active
9/13
Last Updated
Strength: 9 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is REGENXBIO Inc. (RGNX) Undervalued or Overvalued in 2026?

According to CirclFi’s 9-model valuation engine, REGENXBIO Inc. (RGNX) appears overvalued as of : the median of 9 independent fair value estimates is $1.55, 87.4% below the current price of $12.27. Estimates range from $0.23 to $10.62. RGNX scores 6.3/10 on fundamental quality and 14/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy REGENXBIO Inc. Stock in 2026? →

Valuation Matrix

9 Intrinsic Value Models vs. Current Price ($12.27)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $1.55 -87.4%
CUCE Ensemble
Low Conviction
 $2.52 -79.5%
First Chicago
Medium Conviction
 $0.74 -94.0%
Dynamic NAV
Medium Conviction
 $3.18 -74.1%

Unlock the Full Matrix

Access 5 additional models including ML-RIV, PWERM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 9 Models →

Cancel anytime · No contracts · Instant access

What Is REGENXBIO Inc. (RGNX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, REGENXBIO Inc.'s intrinsic value is estimated at $3.16, suggesting the stock is overvalued at its current price of $12.27. With 9 out of 9 models flagging downside (-74.2% average return), the market may be pricing in unsustainable growth. Notably, PWERM sees the most upside at -13.4% (fair value: $10.62), while ML-RIV is the most conservative at -98.1% ($0.23). The spread between these extremes — +84.7% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About RGNX?

9 of 13 models are currently active for RGNX. All 9 active models suggest the stock trades above fair value. The Bayesian DCF estimates RGNX's intrinsic value at $1.55, implying -87.4% downside from the current price. See which stocks rank higher →

How Does RGNX Rank in Biological Products, (No Diagnostic Substances)?

Among 134 Biological Products, (No Diagnostic Substances) stocks, RGNX ranks #34 by Quality of Company score. CirclFi's QOC score of 6.3/10 evaluates 32 fundamental signals. A score of 6.3 indicates above-average quality.

See all Most Undervalued Biological Products, (No Diagnostic Substances) Stocks →

REGENXBIO Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is RGNX a Value Trap?

CirclFi's Value Trap algorithm assigns RGNX a score of 14/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

9 of 13 models are active for REGENXBIO Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, REGENXBIO Inc.'s fundamental quality profile registers 6.3/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +84.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every RGNX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across RGNX's 9 active models, average confidence is 23%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy REGENXBIO Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biological Products, (No Diagnostic Substances) Stocks Should You Also Analyze?

8 related Biological Products, (No Diagnostic Substances) stocks with 13-model coverage

EXELExelixis, Inc.QOC 10.0HALOHalozyme Therapeutics, Inc.QOC 10.0NBIXNeurocrine Biosciences, Inc.QOC 10.0GILDGilead Sciences, Inc.QOC 9.7PLXProtalix BioTherapeutics, Inc. QOC 8.6BIIBBiogen Inc.QOC 8.4IMCRImmunocore Holdings plcQOC 7.9TECHBio-Techne CorpQOC 7.8

Read investment analysis: EXEL · HALO · NBIX · GILD · PLX

See all Biological Products, (No Diagnostic Substances) stocks ranked →

Frequently Asked Questions About REGENXBIO Inc.

What is REGENXBIO Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, REGENXBIO Inc. (RGNX) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $1.55. The Quality of Company score is 6.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is RGNX overvalued or undervalued right now?

At $12.27, 0 of 9 active models suggest RGNX may be undervalued, while 9 indicate potential overvaluation. The median of all 9 fair value estimates is $1.55, 87.4% below the current price of $12.27 — a consensus view that RGNX is overvalued. The assessment depends on which methodology best fits REGENXBIO Inc.'s business model in Biological Products, (No Diagnostic Substances).

What does a Quality of Company score of 6.3 mean for RGNX?

REGENXBIO Inc.'s QOC of 6.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on RGNX?

CirclFi analyzes RGNX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 9 of 13 are active for this stock. Read the full methodology →

Is RGNX a value trap in 2026?

REGENXBIO Inc.'s Value Trap score is 14/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 9-model valuation engine, REGENXBIO Inc. (RGNX) has a median fair value of $1.55 — 87.4% below the current price of $12.27 — as of 2026-07-15.” Source: circlfi.com/stock/RGNX/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 9 mathematical frameworks give you clarity on RGNX.

Unlock All 9 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access